Scientific research can be confusing and overwhelming. We not only fund research, but we also help you understand RET-positive research and what it means for current treatment options and future therapies.
Research
Research Funding
We fund and facilitate research for treatments so that more RET-positive lung cancer patients will live fuller, healthier lives.
Our researchers are investigating resistance to currently available targeted therapies, including:
- Identifying new, more effective combination therapies for RET-inhibitor resistant disease
- Testing innovative adaptive T cell therapies such as TCR immunotherapies for RET cancers
- Generating new RET cancer preclinical models, including cell likes and patient-derived xenograft mouse models
We also work closely with the offices of leading cancer research institutions to assist them in securing grant funding for continued RET-positive research.
Since our inception in 2021, we have awarded more than $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.
Webinars
We host webinars that bring together members of the scientific community with patients and caregivers to explain the latest research findings.
2023 RET Research Update
2022 RET Research Update
